Federal law quietly strips states of dietary supplement oversight

What it does

This bill amends federal law to prohibit states from imposing their own dietary supplement regulations that differ from or exceed federal FDA standards, unless the FDA grants a specific exemption. States can apply for exemptions only if their rule is stricter than federal law or addresses a compelling local condition without conflicting with federal requirements. The effect is to centralize dietary supplement oversight at the federal level and block state-level consumer protections that go beyond FDA minimums.

Why we flagged it

The bill's operative mechanism is a federal preemption clause that strips states of regulatory authority over dietary supplements and centralizes control at the FDA level. While framed as 'uniformity,' the effect is to block state-level protections and shift power to the federal regulator, which has historically taken a lighter-touch approach to dietary supplement oversight than many states.

What the text implies

• States that have enacted stricter labeling, purity, or adverse-event-reporting requirements for dietary supplements would be forced to abandon them unless FDA grants an exemption—a discretionary process with no timeline or appeal mechanism.
• The exemption pathway requires states to prove a 'compelling local condition' AND show compliance with federal law, a dual burden that may be difficult to meet; FDA has no obligation to grant exemptions and can impose conditions.
• Dietary supplement manufacturers gain a single, uniform federal regulatory floor rather than facing a patchwork of state rules, reducing compliance costs and potential liability exposure across state lines.
• Consumers in states with historically stricter dietary supplement oversight (e.g., California, New York) lose access to those protections unless the state successfully petitions for an exemption.
• The bill does not define 'compelling local condition,' leaving the standard vague and subject to FDA interpretation, which may narrow state authority further through regulatory guidance.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens lose the ability to rely on state consumer protections for dietary supplements that exceed federal standards. State-level enforcement, labeling requirements, and safety standards that go beyond FDA minimums are preempted, reducing the total regulatory floor available to consumers. The exemption pathway is narrow and discretionary, giving states no guaranteed right to protect their residents.

Who stands to gain

• dietary supplement manufacturers
• dietary supplement distributors
• contract manufacturers serving the supplement industry

Named in the bill

FDA (Food and Drug Administration), Federal Food, Drug, and Cosmetic Act, Section 403A, state governments, dietary supplement industry

Where it stands

• Feb 4, 2026 — Introduced · Congress.gov: “Introduced in House”
• Feb 4, 2026 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

11 lobbying clients named this bill on 11 disclosure filings across 2 quarters, Mar 2026 to Jun 2026. Those filings disclosed $1,179,750 in lobbying spend. A filing names 7 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 92% of bills with at least one filing.

Nicholas Langworthy, the sponsor, reported $1,046,611 in PAC receipts in the 2026 cycle.

• Haleon Us Holdings LLC — $260,000 on 1 filing
• Consumer Healthcare Products Association — $199,750 on 1 filing
• Kerry Inc. and Affiliates Owned By Kerry Holding Co Including Niacet Corporation — $160,000 on 1 filing
• Novozymes North America, Inc. — $140,000 on 1 filing
• Unilever United States, Inc. — $130,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.